{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Dose limiting toxicity defined as an adverse event or adverse drug reaction experienced by the participants during 6 weeks of treatment Cycle 1","groups":[{"description":"JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles","id":"OG000","title":"Phase I - JNJ-26866138 0.7 mg/m2 Group"},{"description":"JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles","id":"OG001","title":"Phase I - JNJ-26866138 1.0 mg/m2 Group"},{"description":"JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles","id":"OG002","title":"Phase I - JNJ-26866138 1.3 mg/m2 Group"}],"paramType":"NUMBER","populationDescription":"Dose Limiting Toxicity set, Which includes all 18 participants in the Phase I","reportingStatus":"POSTED","timeFrame":"6 weeks","title":"Number of Participants With Dose Limiting Toxicity During the Phase I (Cycle 1)","type":"PRIMARY","unitOfMeasure":"Participants"}